To assess the ability of NTP to modulate surface CD47 on cancerous cells, we used three different cancer cell types: glioblastoma (U87), head and neck cancer squamous cell carcinoma (SC263), and melanoma (A375). The gene discussed is CD47; the disease is head and neck cancer.